ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 334,73
-0,28%
Dow Jones
42 992,21
0,00%
DAX
19 909,14
-0,25%
Brent Oil
74,035
0,56%
Bitcoin
92 872,50
-0,69%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. IGC Pharma Inc (IGC)

  7. IGC Pharma Inc (IGC) Actualités

IGC

IGC Pharma (IGC)

IGC Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:AMEX:IGC
DateHeureSourceTitreSymboleSociété
25/11/202414h30Business WireIGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's TreatmentAMEX:IGCIGC Pharma Inc
12/11/202422h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
27/09/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
27/09/202422h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
18/09/202414h00Business WireIGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentAMEX:IGCIGC Pharma Inc
04/09/202414h00Business WireIGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
27/08/202401h00Business WireIGC Announces Results of its 2024 Annual Stockholders MeetingAMEX:IGCIGC Pharma Inc
22/08/202415h00Business WireIGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
20/08/202414h00Business WireIGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 AgonistAMEX:IGCIGC Pharma Inc
14/08/202422h23Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]AMEX:IGCIGC Pharma Inc
09/08/202403h30Business WireIGC Pharma Reports First Quarter Fiscal 2025 ResultsAMEX:IGCIGC Pharma Inc
18/07/202415h00Business WireIGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price TargetAMEX:IGCIGC Pharma Inc
09/07/202420h17Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:IGCIGC Pharma Inc
09/07/202415h10Business WirePreclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety ProfileAMEX:IGCIGC Pharma Inc
08/07/202422h07Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:IGCIGC Pharma Inc
25/06/202415h00Business WireIGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
25/06/202401h30Business WireIGC Reports Financial Results for Fiscal Year Ended March 31, 2024AMEX:IGCIGC Pharma Inc
18/06/202415h00Business WireIGC Pharma to Participate in Fireside Chat with Ascendiant Capital MarketsAMEX:IGCIGC Pharma Inc
10/06/202415h00Business WireIGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 TetrahydrocannabinolAMEX:IGCIGC Pharma Inc
28/05/202415h00Business WireIGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1AMEX:IGCIGC Pharma Inc
22/05/202403h20Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipAMEX:IGCIGC Pharma Inc
21/05/202420h00Business WireIGC Pharma to Attend BIO International Convention 2024AMEX:IGCIGC Pharma Inc
14/05/202403h53Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
16/04/202413h00Business WireIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoAMEX:IGCIGC Pharma Inc
09/04/202415h00Business WireIGC Pharma Adds Advisor in Artificial IntelligenceAMEX:IGCIGC Pharma Inc
26/03/202420h00Business WireIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockAMEX:IGCIGC Pharma Inc
20/03/202416h00Business WireIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationAMEX:IGCIGC Pharma Inc
20/03/202412h00Business WireIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024AMEX:IGCIGC Pharma Inc
12/03/202420h00Business WireIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s PipelineAMEX:IGCIGC Pharma Inc
28/02/202419h00Business WirePromising Results: TGR-63 Enhances Memory in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
 Showing the most relevant articles for your search:AMEX:IGC

Dernières Valeurs Consultées

FTSE
UKX
FTSE 100
NASDAQ
MSFT
Microsoft
COIN
ADAUSD
Cardano
EU
DG
Vinci
EU
PX4
SBF 120
NASDAQ
AAPL
Apple
EU
BEL20
Bel 20
COIN
SOLUSD
Solana
EU
RNO
Renault
EU
MC
Lvmh Moet Hennessy Louis...
EU
CS
Axa
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
EU
RI
Pernod Ricard
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés